Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial

BACKGROUND: To determine the minimum survival benefits that patients, and their clinicians, judged sufficient to make adjuvant chemotherapy (ACT) worthwhile, in addition to pelvic radiotherapy, for women with high risk and advanced stage endometrial cancer. METHODS: Eighty-three participants in the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Blinman, Prunella, Mileshkin, Linda, Khaw, Pearly, Goss, Geraldine, Johnson, Carol, Capp, Anne, Brooks, Susan, Wain, Gerard, Kolodziej, Ilka, Veillard, Anne-Sophie, O'Connell, Rachel, Creutzberg, Carien L, Stockler, Martin R
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104894/
https://ncbi.nlm.nih.gov/pubmed/27764842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.323
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados